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considered together. Compared with the widespread appli-
cation of HCV RNA test by quantitative RT-PCR technique,
HCV core antigen detection may be an alternative indicator
in the diagnosis of hepatitis C virus infections and in moni-
toring the status of infectious individuals. However, the ap-
plication and signiﬁcance of HCV core antigen assay and its
correlation with HCV RNA detection are still not well inves-
tigated, especially on the background of HIV coinfection.
Methods: In this study, we analyzed and compared the
serological and virological characteristics of HCV viremia-
positive and viremia-negative patients in a total of 354 HCV
and/or HIV seropositive subjects enrolled from a village of
central China. Besides HCV-related hepatopathic variables
including clinical status, ALT, AST, anti-HCV Abs, as well as
the altered CD4+/CD8+ T cell counts, HCV core antigen and
HCV viral load were also measured.
Results:
1. The 354 participants were divided into 5 groups
(HIV-noninfected CHC (129/354, 36.44%), HIV-infected
CHC (98/354, 27.68%), HIV-1-noninfected SVC (65/354,
18.36%), HIV-infected SVC (44/354, 12.43%), and HIV
infection (18/354, 5.08%) alone) depending on the
existence of anti-HCV antibody, anti-HIV antibody, and
HCV viral load.
2. No signiﬁcant difference of either ALT (X2 = 0.221,
p = 0.638) or AST (X2 = 0.018, p = 0.895) was found
between the HCV mono-infection (HIV-noninfected CHC,
44.96% for ALT and 44.18% for AST) group and the
HCV/HIV coinfection (HIV-infected CHC, 41.84% for ALT
and 45.92% for AST) group. Interestingly, there were
signiﬁcant differences for ALT (X2 = 3.854, p = 0.05) and
AST (X2 = 13.722, p < 0.001) between the HIV-noninfected
SVC (10.78% for ALT and 3.08% for AST) and the HIV-
infected SVC (25.00% for ALT and 27.08% for AST).
3. 96.90% HIV-noninfected CHC patients and 97.96% HIV-
infected CHC patients were reactive to the HCV core
antigen measurement. And for the ﬁrst time, we
reported that serum concentrations of HCV core antigen
were highly correlated with HCV RNA levels in both HCV
mono-infected (r = 0.8083, p < 0.001) and HCV/HIV co-
infected (r = 0.9524, p < 0.001) patients in this study.
4. HCV core antigen concentration was negatively corre-
lated (r = 0.2847, p = 0.0083) with CD4+ T cell counts
less than 1000/ml, and S/CO ratio of anti-HCV antibody
(r = 0.3155, p = 0.0033) was positively correlated with
CD4+ T cell counts in HIV-infected CHC patients with
CD4+ T cell counts, while no correlation was found
between HCV RNA level and CD4+ T cell count.
Conclusions: In total, our ﬁndings demonstrated that there
were distinctive serological and virological characteristics
of serum HCV RNA positive and negative hepatitis C patients
with or without HIV-1 coinfection. Importantly, there was
an excellent correlation between plasma HCV viral load
and the concentration of HCV core protein not only in the
HCV mono-infected population but also in the HCV/HIV-1
coinfected population. The HCV antigen assay detected
the vast majority of HCV RNA positives with or without
HIV infection. Considering HCV, core antigen testing has a
comparable sensitivity to HCV RNA qPCR. HCV core antigen
concentration, but not HCV RNA level, was negatively
correlated with CD4+ T cell counts. Our data suggested that
quantitative detection of plasma HCV core antigen may be a
better indicator of peripheral HCV level than HCV RNA level
when evaluating the association between HCV replication
and host immune status in HCV/HIV coinfected patients.
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Objectives: To elucidate impact of amino acid (aa)
substitutions of interferon sensitivity determining region
(ISDR) of HCV on the outcome of combined pegylated
interferon/ribavirin therapy in the patients with chronic
hepatitits C virus genotype 1b infection in Southern China.
Methods: A total of 44 patients with chronic HCV 1b
infection who received 48 weeks of combination therapy
and 6-month follow up were analyzed retrospectively.
Clinical and laboratory parameters including gender, age,
route of transmission, ALT, AST, quantiﬁcation of HCV RNA
and the substitution number of ISDR were assessed. The
binary logistic regression analysis to identify those that are
independently associated with the early virological response
(EVR), end of treatment virological response (ETVR) and
sustained virological response (SVR) was conducted.
Results: Sequences of ISDR were compared with HCV
J strain.11 of 44 isolates were wild type, 32 were
intermediate type (2 3 aa substitutions) and only 1 was
mutant type (4 or more aa substitutions). The SVR rate
was 43.2% (19/44). The statistical analysis indicated there
was a signiﬁcant correlation between the aa mutation
number (2) in HCV ISDR and SVR/EVR (P= 0.005/P= 0.018);
and the independent variables related to SVR were the
mutation number in ISDR (OR, 17.038; P= 0.011), age group
(40 years) (OR, 12.259; P= 0.011) and AST (OR, 1.021;
P= 0.020).
Conclusions: These results support the hypothesis of aa
substitution at ISDR of HCV genotype 1b could predict SVR.
Although the aa sequence of ISDR is conservative, and the
mutant type of ISDR (4 or more aa substitutions) is rare in
Southern China, it is interesting that the mutation number
of ISDR as a predictor of SVR can decreased from 4 to 2
when using PEG-IFN plus RBV combination therapy.
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Background: The effective standard therapeutic regimen
using PEG-IFN in combination with RBV has led to improved
sustained viral response rates for patients with chronic
hepatitis C (CHC). However, PEG-IFN is very expensive;
most patients cannot afford the treatment in China. The
recombinant IFN-2b is much cheaper and has been proven
to be safe and effective. The low cost allows to treat a
wide range of patients.
Methods: A total of 264 treatment-naïve patients with
CHC received the treatments of recombinant IFNa-2b (5
MIU/qod) and RBV (900mg/d). The efﬁcacy and safety of
the treatment were investigated and inﬂuencing factors
were evaluated.
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Results: 43.9% of patients achieved a rapid virological
response (RVR) and 69.1% of patients had a complete
early virological response (cEVR). The serum alanine
aminotransferase (ALT) normalization rates were 70.9%
and 86.2% at week 4 and 12. Analyzing IL-28B variation
(rs12979860), more proportions of patients with the
CC genotype (46.7% or 75.3%) achieved a RVR or a
cEVR respectively, compared to patients with the CT/TT
genotypes (23.8% or 35.3%). However, in a multivariable
logistic regression model, the IL-28B genotype was not
shown statistically to be a predictive value for RVR or cEVR.
Baseline predictive factors for RVR included the serum HCV
RNA <4×105 IU/mL (OR: 0.16) and gender (in females,
OR: 0.39). The HCV genotype was only a predictive factor
for cEVR (2a vs 1b, OR: 8.80). The treatments for 28 patients
were discontinued due to adverse events such as anaemia
and fatigue.
Conclusion: The recombinant IFNa-2b therapy demon-
strated a potent anti-virus effect and a signiﬁcant
biochemical improvement. It has good tolerance and safety
proﬁles. The serum HCV RNA, gender and the HCV genotype
were identiﬁed as valuable predictors for patients who
responded to IFN/RBV treatments in the present study.
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Background: Hepatic ﬁbrosis develops as a response to
HCV-related chronic liver injury. Proliferative response of
hepatocytes is crucial in HCV infection as hepatocytes are
the primary site for HCV replication and receive different
cellular stress from surrounding cells.
Objectives: To study intrahepatic expression of
transforming growth factor beta-1 (TGF-b1), Angiotensin
converting enzyme-2 (ACE-2), alpha smooth muscle actin (a-
SMA) and endoglin, a TGF-b receptor in liver biopsies from
patients with chronic HCV infection and correlate results
with stage of ﬁbrosis and necro inﬂammatory activity.
Methods: Forty two patients with chronic HCV infection,
20 females, 22 males, median age 34.5 years whose liver
biopsy showed different stages of ﬁbrosis were included
in this study. Tissue expression of TGF-b1, ACE-2, a-SMA
were investigated by immunohistochemistry on parafﬁn
embedded liver tissues and tissue expression of endoglin
by immunoblotting. Immunoreactive semiquantitative score
was applied to compare immunohistochemical results with
histological ﬁndings according to Ishak scoring system for
histological activity index (HAI) and stage of ﬁbrosis.
Results: Statistical analysis of data revealed a signiﬁcant
correlation between tissue TGF-b1, ACE-2, a-SMA
andendoglin with stage of ﬁbrosis; p < 0.001, 0.05, 0.01,
0.001respectively. Moreover, TGF-b1 correlated signiﬁcantly
with HAI, p < 0.05.
Conclusion: Data from this study provide evidence for
the implication of ACE-2 and TGF-b receptors in the
pathogenesis of hepatic ﬁbrosis as well as a possible role in
prognostic and therapeutic management of cirrhosis.
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Background: The emergence of serious infections caused
by multidrug-resistant Gram-negative bacteria (MDR-GNB)
presents a signiﬁcant therapeutic challenge to clinicians.
MDR-GNB can express altered penicillin-binding proteins
(PBPs) or produce b-lactamases, which hydrolyse the
antibiotic. They can also express efﬂux systems that
actively pump the drug into the extracellular environment
or reduce the permeability of the outer membrane by
mutation of porins. The growing resistance to carbapenems
amongst these strains is causing particular concern and new
antibiotics able to overcome these resistance mechanisms
are urgently needed.
Methods: Antimicrobial susceptibility testing was performed
by broth microdilution according to CLSI recommendations
but using Iso-Sensitest broth supplemented with 16mg/L
2,2’-bipyridyl to induce iron uptake. The efﬁcacies of
BAL30072 and comparators were tested against MDR-GNB
in a mouse model of septicaemia.
Results: The siderophore sulfactam BAL30072 emerged as
the most potent compound amongst a series of novel
monocyclic beta-lactam derivatives. BAL30072 was active
against a wide-range of MDR-GNB including difﬁcult to treat
organisms such as P. aeruginosa and Acinetobacter species.
It was shown to exploit essential iron uptake systems to
bypass the mutated porins, not to be a substrate for efﬂux
pumps and to be stable towards many beta-lactamases,
especially carbapenemases. BAL30072 showed good efﬁcacy
against carbapenem-resistant strains in the septicaemia
model.
Conclusions: BAL30072 is a novel siderophore sulfactam
with potent activity against MDR-GNB. The in-vitro activity
translates into a protective effect in an animal model of
infection. The compound, which is currently in phase I
clinical testing, addresses the growing problems caused by
multi-resistant Gram-negative bacteria.
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Background: Community-acquired methicillin-resistant
Staphylococcus aureus (CA-MRSA), including those encoding
Panton-Valentine leucocidin (PVL), are often described more
susceptible to most antimicrobial agents except for non-b-
lactam antibiotics, than hospital-acquired MRSA. Recently,
separate studies have reported the emergence of multidrug-
resistant CA-MRSA in certain clones. In this study, the
multidrug-resistant CA-MRSA isolates were detected and
their distribution was determined in different clones in
Mainland China.
